Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] by Quarter
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%) (%)
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4]: -98.9% in Q3 2024, down 1.1 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2024 figure comes from
“|| Intl | 1 | 41 | (97.7) | (98.9) | 1.2”
Source: Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2024 | Sep 29, 2024 | -98.9% | -1.1 pts | Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗ |
| Q2 2024 | Jun 30, 2024 | -39.7% | +7.7 pts | Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗ |
| Q1 2024 | Mar 31, 2024 | -96.7% | – | Form 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗ |
| Q4 2023 | Dec 31, 2023 | -95.2% | -50.2 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| Q3 2023 | Oct 1, 2023 | -97.8% | – | Form 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗ |
| Q2 2023 | Jul 2, 2023 | -47.4% | – | Form 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗ |
| Q4 2022 | Jan 1, 2023 | -45.0% | – | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] (%), quarterly Q4 2022–Q3 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-covid19-intl-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.